Keeping a food diary on a GLP-1

Food is part of the approved use

The indication section of the Wegovy®, Zepbound®, Saxenda® and Foundayo™ labels says each is meant to be used alongside a reduced-calorie diet and more physical activity ^[1][2][3][4]. The Wegovy®, Zepbound® and Saxenda® dosing sections repeat this as an instruction to prescribers ^[1][2][3]. For Rybelsus® and Ozempic® tablets, which treat type 2 diabetes, the label uses the phrase “an adjunct to diet and exercise” ^[5].

NIDDK makes the same point for weight-management medicines in general: they do not replace healthy eating or physical activity, and they work best inside a lifestyle programme, which can also deal with things like eating triggers ^[6].

What trial participants were asked to do

The Zepbound® label describes the lifestyle part of its main weight trials. Everyone, whether on the medicine or placebo, received instruction on a reduced-calorie diet with a deficit of about 500 kcal a day, counseling to increase physical activity, and counseling on behaviour change strategies to stick with both ^[2]. The Wegovy® label describes the same deficit for most of its trials, the Saxenda® trials used it too, and the Foundayo™ trials included reduced-calorie diet instruction as part of a standard lifestyle programme without naming a figure ^[1][3][4].

This matters when you read trial results: the weight loss reported in the labels came from the medicine plus this programme, compared with the programme alone.

What the labels leave to your care team

None of the labels gives a calorie target, a macro split or a meal plan for an individual. A 500 kcal deficit describes a reduction used in the trials, not a fixed daily intake that applies to everyone.

MedlinePlus asks people on semaglutide to follow the eating and exercise advice given by their doctor or dietitian ^[8]. If you want a calorie or protein target, that is the person to set it with you, taking into account your health, your medicine and how your appetite has changed.

When meals and medicine meet

Most of these medicines do not tie the dose to a meal, but the daily semaglutide tablets do, and a diary that records times can show whether the waiting period is being kept. The table collects what each US label says.

What the medicine changes about eating

The labels explain why eating shifts on these medicines. Semaglutide and tirzepatide decrease calorie intake, and the labels say the effect is likely mediated by appetite; the Foundayo™ label says it decreases food intake ^[1][2][4]. The European product information goes further: for tirzepatide (Mounjaro® in the EU) it describes more satiety and fullness, less hunger and less intense food cravings, and for liraglutide more fullness and less hunger ^[9][10].

A diary does not replace that effect; it shows you how it plays out in your meals. Smaller portions, skipped meals or a day when only a few foods appeal are all worth writing down, because they are the details a dietitian needs to judge whether you are getting enough to eat. Our article on eating with a low appetite looks at that side in more detail.

What NIDDK says about tracking

In its guide to changing habits, NIDDK describes tracking as a way to spot strengths, find what could improve and stay on course. It suggests recording how you felt as well as what you did, and it reminds readers that a setback does not mean failure ^[7].

For a food diary that translates into a few words on hunger, fullness or mood next to the meal, rather than a detailed count. The aim is a record that is honest and easy to keep, not one that is complete.

A diary format that stays light

• What you ate and roughly how much, in a few words per meal.
• The time, so meals can later be lined up with your doses.
• How hungry you were before and how full afterwards, on a simple scale.
• Any stomach symptoms after the meal, such as nausea, fullness or heartburn.
• Water and other drinks, because the Wegovy® Medication Guide asks you to drink fluids to lower the chance of dehydration when you have stomach side effects ^[1].

Linking meals to symptoms and doses

Nausea, vomiting, diarrhea and constipation are among the most common side effects in the labels, and in the main Zepbound® trials most nausea, vomiting and diarrhea occurred during dose escalation and eased over time ^[1][2]. A diary that sits next to your dose history can show whether a certain kind of meal is often followed by trouble, or whether symptoms cluster in the days after a shot.

Bring those patterns to your appointment rather than drawing conclusions alone. Some stomach symptoms are not a diet question at all: the Medication Guide treats severe stomach pain that will not go away, signs of a gallbladder problem and stomach symptoms that keep going as reasons to contact your provider ^[1]. They are listed in the box below.

Keeping it from becoming a chore

A diary is a tool, not a test. Missing a day is fine; the useful part is the pattern over weeks. If logging starts to make you anxious about food, tell your clinician; they may prefer a lighter record or another approach.

It also helps to decide in advance what you will look at and when, for example a quick review once a week, instead of checking every entry as you go. Before a planned surgery or procedure, mention your GLP-1 to the team as the Wegovy® label asks, since the medicine slows stomach emptying ^[1].

Wegovy®, Ozempic®, Rybelsus® and Saxenda® are registered trademarks of Novo Nordisk A/S. Zepbound® and Mounjaro® are registered trademarks and Foundayo™ is a trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Novo Nordisk or Eli Lilly.

When to get help